TheraVet Broadens Significantly its BIOCERA-VET® Product Line Through Major Distribution and Research Agreements
22 Novembre 2021 - 05:45PM
Business Wire
- Addition of two new complementary lines of veterinary bone
substitutes to BIOCERA-VET® portfolio
- Access to 3D-bioprinted customized bone pieces for
sophisticated bone graft vet surgeries
- Research collaboration on new generation proprietary bone
substitutes for veterinary applications
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets, today
announces a partnership significantly expanding TheraVet’s bone
substitutes portfolio with (i) 2 new exclusive and complementary
bone graft lines, (ii) 3D-bioprinted bone endoprostheses for
patient-tailored bone grafting surgeries & (iii) development of
novel generation proprietary products.
Thanks to an exclusive worldwide distribution agreement with
INNOTERE, one of the undisputed leader in bone biomaterials
(Radebeul, Germany), TheraVet broadens its offer of bone
substitutes to the vet orthopedic surgeons with 2 new exclusive
lines of biomaterials: first with first-in-kind ready-to-use
injectable calcium phosphate-based bone cement pastes with
prolonged working time particularly well-suited for
minimally-invasive complex bone grafting procedures and second with
biosynthetic granules of ultra-fine size.
Moreover, TheraVet adds to its portfolio 3D-bioprinted
calcium-phosphate-based bone substitutes. This technology allows
the manufacturing of complex implants specifically designed
according to patient and surgeon needs while ensuring optimal
physico-chemical, biocompatibility and resorbability properties.
One contemplated application is the supply of personalized
biocompatible endoprotheses in the management of canine
osteosarcoma.
Finally, thanks to the R&D agreement, new-generation bone
substitutes will be jointly developed. These R&D programs
relate to the design, development and industrialization of
innovative bone substitutes (i) with enhanced rheofluidifying
properties in order to facilitate their injectability, increase
their workability, and globally improve their ergonomics, (ii) with
improved osteogenic/bone-forming properties in order to fasten and
improve bone consolidation and healing and (iii) combined with
active molecules, therefore acting as local drug delivery device.
In this joint collaboration agreement, each party will file its own
patents, allowing TheraVet to strenghten its intellectual property
position with new proprietary bone substitutes.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
concludes: “This partnership is a great opportunity to expand
TheraVet’ bone substitutes portfolio. Indeed, INNOTERE has an
impressive track-record in developping innovative high added-value
bone biomaterials for human applications that will certainly be
profitable for the veterinary market”.
About TheraVet SA TheraVet is a veterinary biotechnology
company specialising in osteoarticular treatments for animals. The
Company develops targeted, safe and effective treatments to improve
the quality of life of pets suffering from osteoarticular diseases.
For pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Gosselies, Belgium, and it has a subsidiary in the US. For more
information, visit the TheraVet website Or follow us on LinkedIn /
Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122006312/en/
TheraVet Sabrina Ena Chief Operating Officer
Sabrina.ena@thera.vet
Julie Winand Chief Corporate Officer julie.winand@thera.vet Tel:
+32 (0) 71 18 32 49
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024